is our passion
Home / Projects / Platform for the Discovery of Alzheimer’s Disease Mechanisms and Treatments

Platform for the Discovery of Alzheimer’s Disease Mechanisms and Treatments

NOMIS Project 2017

— 2023

There is an urgent need to clarify the brain processes involved in the development of Alzheimer’s disease (AD) and to use this information to discover effective ways to treat and prevent the disease. While studies in animal, cellular and other laboratory models play essential roles in this endeavor, detailed molecular data from persons with and without AD are needed to further inform these experimental studies and clarify the extent to which findings are relevant to this fundamentally human disease.

The project Platform for the Discovery of Alzheimer’s Disease Mechanisms and Treatments aimed to develop an unprecedented public resource of detailed gene expression data from human brain cells and regions that differ in the vulnerability or resilience to AD and help to galvanize the discovery of disease mechanisms, risk factors and treatments. The project capitalized on high-quality brain tissue from 100 longitudinally, neuropathologically and genetically characterized brain donors with and without AD. Emerging big data analysis techniques were employed in an effort to discover molecular networks involved in the disease and molecular drivers of these networks, including those that could be targeted by new or repurposed treatments.

This platform fostered interactions between researchers involved in studies of the human AD brain and experimental researchers who validate the molecular drivers, seek to clarify the generalizability of their own findings to the human disease, and discover paths for future treatments. In addition, it provided a foundation to develop one of the largest basic and translational neuroscience programs for the fight against AD and other neurodegenerative diseases.

The Platform for the Discovery of Alzheimer’s Disease Mechanisms and Treatments project was led by Eric Reiman, Kendall Van Keuren-Jensen, Thomas Beach, Ben Readhead and Joel Dudley from Banner Alzheimer’s Institute, Banner Sun Health Research Institute, the Translational Genomics Research Institute (TGen), the Arizona State University–Banner Neurodegenerative Disease Research Center, and the Arizona Alzheimer’s Consortium.


NOMIS Researcher(s)

Executive director of the Banner Alzheimer's Institute, CEO of Banner Research, and senior scientist at the Translational Genomics Research Institute
Banner Alzheimer’s Institute

Project News

When NOMIS researcher Dr. Eric Reimann was invited to join the Arizona Alzheimer Consortium in Phoenix, he was a practicing psychiatrist who did not know much about the disease. Today, […]


Project Insights

Abstract: The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Trial evaluated the anti-oligomeric amyloid beta (Aβ) antibody therapy crenezumab in cognitively unimpaired members of the Colombian presenilin 1 (PSEN1) E280A kindred. We report availability, methods employed to protect confidentiality and anonymity of participants, and process for requesting and accessing baseline

Introduction: Autosomal-dominant Alzheimer’s disease (ADAD) represents a crucial population for identifying prevention strategies that might modify disease course for cognitively unimpaired individuals at high imminent risk for developing symptoms due […]